Spurred on by the Trump administration’s embrace of psychedelic medicine, researchers are experimenting with new — and not so new — forms of the anesthetic.

Certain viruses attack bacteria and can sometimes clear antibiotic-resistant infections. Researchers said they had tailored a virus to attack one patient’s illness.

The agency had initially refused to even review the application but reversed course after a public outcry.

The agency is considering whether compounding pharmacies should be allowed to produce BPC-157, TB-500 and other previously banned peptides.

In an all-day hearing, the agency’s scientists argued against allowing broad access to unproven drugs that the agency had banned three years ago.

The affected products were shipped starting June 29 and have expiration dates through Aug. 3.

The new pills can lower cholesterol levels far below what can be achieved with statins, clinical trials have shown.

Executives unhappy with the agency donated and lobbied President Trump directly. Major companies have already begun to prepare and ship new products.

With support from Markwayne Mullin and Robert F. Kennedy Jr., the kratom industry is pursuing a potentially lucrative policy. Mr. Mullin owns equity in a company that could benefit.

Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.